The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance

We evaluated the effect of the CYP2C19 genotype on the pharmacokinetics and pharmacodynamcis of clopidogrel. Twenty‐four subjects were divided into three groups on the basis of their CYP2C19 genotype: homozygous extensive metabolizers (homoEMs, n = 8), heterozygous EMs (heteroEMs, n = 8), and poor metabolizers (PMs, n = 8). After a single 300‐mg loading dose of clopidogrel on day 1, followed by a 75‐mg daily maintenance dose from days 2 to 7, we measured the plasma levels of clopidogrel and assessed the antiplatelet effect as pharmacodynamics. The mean clopidogrel area under the curve (AUC) for PMs was 1.8‐ and 2.9‐fold higher than that for heteroEMs and homoEMs, respectively (P = 0.013). The mean peak plasma concentration in PMs was 1.8‐ and 4.7‐fold higher than that of heteroEMs and homoEMs, respectively (P = 0.008). PMs exhibited a significantly lower antiplatelet effect than heteroEMs or homoEMs (P < 0.001). From these findings it is clear that the CYP2C19 genotype affects the plasma levels of clopidogrel and modulates the antiplatelet effect of clopidogrel.

[1]  R. Snow,et al.  Review of the Evidence. , 1964, Science.

[2]  T. Aoyama,et al.  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.

[3]  L. Bertilsson,et al.  Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. , 1995, Pharmacogenetics.

[4]  K. Brøsen,et al.  Drug Interactions and the Cytochrome P450 System , 1995 .

[5]  D. Flockhart,et al.  Drug Interactions and the Cytochrome P450 System , 1995, Clinical pharmacokinetics.

[6]  S. Higuchi,et al.  Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. , 1999, British journal of clinical pharmacology.

[7]  J. Herbert,et al.  Identification and Biological Activity of the Active Metabolite of Clopidogrel , 2000, Thrombosis and Haemostasis.

[8]  M. Seyfarth,et al.  Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement , 2001, Heart.

[9]  J. Herbert,et al.  P2y(12), a new platelet ADP receptor, target of clopidogrel. , 2001, Biochemical and biophysical research communications.

[10]  Ji-Young Park,et al.  Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19 , 2002, Clinical pharmacology and therapeutics.

[11]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[12]  M. Maftouh,et al.  Structure and stereochemistry of the active metabolite of clopidogrel. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[13]  D. Flockhart,et al.  Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. , 2002, Pharmacogenetics.

[14]  P. Gurbel,et al.  Durability of platelet inhibition by clopidogrel. , 2003, The American journal of cardiology.

[15]  M. Gawaz,et al.  Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement , 2003, Thrombosis and Haemostasis.

[16]  A. Peregrina,et al.  CYP2C19‐ and CYP3A4‐Dependent Omeprazole Metabolism in West Mexicans , 2003, Journal of clinical pharmacology.

[17]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[18]  Paul B. Watkins,et al.  Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction , 2003, Circulation.

[19]  L. Waskell,et al.  The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[20]  R. S. Alpan,et al.  Bioequivalence Study of Clopidogrel Bisulfate Film-coated Tablets , 2004, Arzneimittelforschung.

[21]  E. Trabetti,et al.  807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[22]  P. Watkins,et al.  Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance , 2004, Circulation.

[23]  C. Adithan,et al.  The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians , 2005, European Journal of Clinical Pharmacology.

[24]  C. Macaya,et al.  High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. , 2004, European heart journal.

[25]  C. Macaya,et al.  Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. , 2005, Thrombosis research.

[26]  J. Diodati,et al.  Resistance to clopidogrel: a review of the evidence. , 2005, Journal of the American College of Cardiology.

[27]  Gene Expression Profiling of Acute Myeloid Leukemia with Multilineage Dysplasia (AML-MD) Reveals a Biological Diversity Related to Underlying Cytogenetics but Also Identifies a Distinctive Profile in Normal Karyotype AML-MD. , 2006 .

[28]  P. Gandhi,et al.  Possible mechanisms of drug-induced aspirin and clopidogrel resistance , 2006, Journal of Thrombosis and Thrombolysis.

[29]  V. Knappertz,et al.  Aspirin and clopidogrel resistance: an emerging clinical entity. , 2006, European heart journal.

[30]  R. Storey,et al.  Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy , 2006, Platelets.

[31]  J. Suh,et al.  Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel , 2006, Canadian Medical Association Journal.

[32]  A. Bura,et al.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.

[33]  M. Gilard,et al.  Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin , 2006, Journal of thrombosis and haemostasis : JTH.

[34]  K. Winters,et al.  Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently , 2007, Clinical pharmacology and therapeutics.

[35]  J. Hulot,et al.  Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects , 2007, Journal of thrombosis and haemostasis : JTH.

[36]  S. Iturria,et al.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.

[37]  B. Giusti,et al.  Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients , 2007, Pharmacogenetics and genomics.

[38]  K. Winters,et al.  Clopidogrel poor responders: An objective definition based on Bayesian classification , 2007, Platelets.

[39]  J. Jukema,et al.  Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. , 2007, American heart journal.

[40]  A. Maree,et al.  Aspirin and clopidogrel resistance. , 2007, Hematology. American Society of Hematology. Education Program.

[41]  F. Mach,et al.  Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. , 2008, Thrombosis research.

[42]  Ji-Young Park,et al.  Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects , 2008, European Journal of Clinical Pharmacology.